Bio-Rad

Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, driven by growth in both its Life Science and Clinical Diagnostics businesses.

The assay could provide detection of HBV infection at early stages, potentially preventing progression to cirrhosis or hepatocellular carcinoma.

As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.

The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.

The firm saw an increase in sales for both the life science and clinical diagnostics segments.

The firm has provided glimpses into its strategies for developing a line of regulated droplet digital PCR tests in a number of recent forums.

Some of the biggest players in the life science tools and diagnostics industries including Danaher, Agilent, and Hologic presented on day two of the conference, discussing plans for 2018.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.